Autoimmune Blistering Diseases Study

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
University of Pennsylvania
Study ID
NCT02753777
Status
Recruiting
Apply to this trial

Conditions

  • Bullous Pemphigoid
  • Pemphigus Foliaceus
  • Pemphigus Vulgaris

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Questionnaires — OTHER

Study Details

Pemphigus and bullous pemphigoid (BP) are severe autoimmune blistering diseases (AIBD) that pose a critical need for new therapeutic approaches. Clinical trials in pemphigus and BP will require the availability of validated disease severity measures that can be used to define primary outcomes.

Key Dates

Start date
Apr 30, 2016
Status verified
Mar 2026
Primary completion
Jan 2, 2030
Completion
Jan 2, 2030

Study Design

Enrollment
150 participants (estimated)

Primary Outcome Measure

Pemphigus Disease Area Index (PDAI) [ Time Frame: one year ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
Hospital of the University of PennsylvaniaPhiladelphiaPennsylvania19104
Victoria P Werth, MD
[email protected]
215-615-2940
Hospital of the University of Pennsylvania, Department of DermatologyPhiladelphiaPennsylvania19104
Victoria P Werth, MD
[email protected]
215-615-2940
Joyce Okawa, RN
[email protected]
215-615-2940
Victoria P Werth, MD (PRINCIPAL_INVESTIGATOR)
University of Pennsylvania, Department of DermatologyPhiladelphiaPennsylvania19104
Victoria P Werth, MD
[email protected]
215-615-2940
Victoria P. Werth, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Philadelphia, PA

By research site
Hospital of the University of Pennsylvania· Philadelphia, PAHospital of the University of Pennsylvania, Department of Dermatology· Philadelphia, PAUniversity of Pennsylvania, Department of Dermatology· Philadelphia, PA

Related Studies